Answers are grounded in this paper and cite their sources.
Objective To explore, in a pilot randomized controlled trial, whether two different preoperative glycemic optimization strategies — a two-week strategy targeting random blood glucose ≤ 200 mg/dL versus a three-month strategy targeting HbA1c < 8.5% — are associated with different surgical site infection (SSI) rates in diabetic men undergoing malleable penile prosthesis implantation (PPI), and to generate effect-size estimates to inform a definitive trial. Because the strategies differ in glycemic metric and target as well as duration, any observed difference cannot be attributed to duration of optimization alone. Patients and methods Forty-two diabetic men with erectile dysfunction and glycated hemoglobin (HbA1c) > 8.5% scheduled for malleable PPI at a single tertiary academic center were randomized 1:1 to Group A (short-term, two-week optimization targeting random blood glucose ≤ 200 mg/dL) or Group B (three-month optimization targeting HbA1c < 8.5%). The primary outcome was SSI within three months. Diabetes was co-managed by the endocrinology service. Given the small size, the study was pre-specified as a pilot; no non-inferiority margin was defined. Results All 42 patients completed follow-up. Baseline HbA1c at enrolment was similar between groups (both > 8.5%; Table 1), but preoperative HbA1c immediately before surgery was significantly higher in Group A than Group B (9.20 ± 0.78% vs. 7.62 ± 0.47%, p < 0.001), reflecting their assigned optimization strategies. Superficial SSI occurred in 3/21 (14.3%) in Group A versus 1/21 (4.8%) in Group B (risk difference 9.5%; OR 2.59; p = 0.606). Post-hoc power for this comparison was ~ 19%. No deep infections requiring prosthesis removal occurred. In an exploratory, descriptive comparison (4 infected vs. 38 non-infected patients), infected patients had a numerically higher mean preoperative HbA1c (9.40 ± 1.76% vs. 8.31 ± 0.88%; p = 0.30, Welch’s t-test) and BMI (27.8 ± 2.5 vs. 24.9 ± 1.6 kg/m²; p = 0.10, Welch’s t-test). Conclusion This pilot was underpowered and observed a non-significant three-fold higher SSI rate with the two-week, glucose-targeted strategy compared with the three-month, HbA1c-targeted strategy. Because the two strategies differ in duration, glycemic metric, and achieved control, this difference cannot be attributed to duration of optimization alone. The data neither establish nor exclude a clinically important difference and must be regarded as hypothesis-generating only; they should not be interpreted as evidence that either strategy is safe or non-inferior to the other. A definitive multicenter trial is warranted, using a prespecified non-inferiority margin, intra/postoperative glucose monitoring, and blinded outcome assessment; our data suggest a preliminary planning estimate of approximately 300 patients, which is unstable because it is derived from only four events. Findings apply specifically to malleable devices.
No takes yet. Share an insight, caveat, or question.
Abdullahi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: